APOL1-Mediated Kidney Disease (AMKD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Apolipoprotein L-1 (APOL1) variants pose a heightened risk of end-stage kidney disease (ESRD) among African American individuals. These coding variants are associated explicitly with non-diabetic chronic kidney disease, focal segmental glomerulosclerosis (FSGS), and HIV-associated nephropathy in patients of African descent. APOL1, a small 42 kd protein primarily found in the kidney and enriched in glomeruli, harbors two allelic variants: G1 (S342G and I384M) and G2 (N388del: Y389del), both altering the APOL1 protein sequence within an anti-trypanosome activity domain. The majority of individuals with recent African ancestry diagnosed with HIV-associated nephropathy (HIVAN), FSGS, and hypertension-attributed ESRD exhibit APOL1-associated kidney disease. Clinical studies on kidney transplantation reveal no significant correlation between APOL1 genotype and serum APOL1 protein levels or kidney disease presence. The persistent disparities in long-term outcomes following kidney transplantation from African American versus European American deceased donors, as well as the heightened risk of subsequent nephropathy among African American living kidney donors, have long been recognized without clear etiology. Notably, recipients of kidneys from African American deceased donors lacking APOL1 renal-risk genotypes exhibit comparable allograft survival to those from European American donors lacking APOL1 renal-risk variants. Moreover, healthy African American living kidney donors with APOL1 high-risk genotypes face a significantly increased likelihood of developing Stage 3 or higher CKD, including ESRD, 12 years post-donor nephrectomy compared to counterparts without APOL1 renal-risk genotypes.

Thelansis’s “APOL1-Mediated Kidney Disease (AMKD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential APOL1-Mediated Kidney Disease (AMKD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of APOL1-Mediated Kidney Disease (AMKD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

APOL1-Mediated Kidney Disease (AMKD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: APOL1-Mediated Kidney Disease (AMKD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033